BVCF, a Shanghai-based life sciences investor, has closed its third fund with $188 million to back upstart biotechs on both sides of the Pacific focused on the booming Asian market.
Boston Scientific has launched its much-hyped S-ICD in Asia, notching the first implant of the under-the-skin system in Hong Kong as it looks to expand the market for the device.
Medtronic is looking to bypass some middlemen in its Turkish operation, buying a controlling stake in one of its distributors and launching a joint venture as it works to expand its share of the growing medical device market.
Bribery allegations against GlaxoSmithKline are no longer confined to China. New claims have forced the pharma giant to open investigations on a second front, with the company now looking into possible corruption in Iraq, the company said Sunday.
WuXi PharmaTech, China's largest pharma outsourcing outfit, is investing in a startup that makes tiny, edible bar codes designed to prevent drug counterfeiting, planning to offer the same technology to its manufacturing customers.
Alongside Swiss drugmaker Ferring and the World Health Organization, Merck is embarking on a multinational effort to develop an easily transportable treatment for excessive bleeding, hoping to curb global rates of postpartum hemorrhage among the world's poorest mothers.
A few days after a similar announcement from GlaxoSmithKline, Sanofi said it plans to scale up its presence in Africa, looking to invest in marketing and R&D in response to the market's continued growth.
Nine months after GlaxoSmithKline's bribery scandal first ignited a corruption hunt among Big Pharma companies in China, drugmakers--GSK excepted--are returning to the strong emerging-markets growth they're accustomed to in the country.
Just days after GlaxoSmithKline announced it would open a new R&D lab and invest more than $200 million in Africa, Sanofi CEO Chris Viehbacher is affirming his country's devotion to Africa, too.
GlaxoSmithKline has long been a leader in producing vaccines for Africa, but now it's going one step further. The British pharma will tailor a portfolio of meds to address specific health needs on the continent and increase the registration of drugs and vaccines it already has, the company said this week.